Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
IQVIA Holdings Inc Schedule 13G filing shows Vanguard Capital Management reports beneficial ownership of 12,714,783 shares of Common Stock as of 03/31/2026. The stake represents 7.49% of the class and Vanguard reports sole dispositive power over those shares.
The filing lists 1,687,800 shares as sole voting power and affirms holdings are reported on behalf of Vanguard affiliates and managed funds. The form is signed 04/30/2026 by Ashley Grim.
Stamps Sheila A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Sheila A. Stamps received a grant of 1,571 deferred shares linked to common stock as compensation. The award is priced at $160.68 per deferred share and increases her directly held deferred share balance to 4,210.
Each deferred share is convertible into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, the deferred shares become settleable when she ceases to be a director, upon a change in control of the company, or upon her death, with no expiry date.
Wims Morris Leslie reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Morris Leslie Wims received a compensation grant of 1,571 deferred shares on common stock. These deferred shares are convertible into an equal number of IQVIA common shares upon settlement under the company’s Non-Employee Director Deferral Plan.
The award increased the director’s directly held deferred share balance to 6,465. The deferred shares become settleable when the director ceases to serve on the board, upon a change in control of the company, or upon the director’s death, and they do not have an expiry date.
Kaelin William G Jr reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director William G. Kaelin Jr. received a grant of 1,571 deferred shares on April 23, 2026. Each deferred share represents the right to receive one share of IQVIA common stock upon settlement under the company’s Non-Employee Director Deferral Plan.
The deferred shares become settleable when he ceases to be a director, upon a change in control of the company, or upon his death. After this award, he beneficially holds 1,571 deferred shares directly, with no stated expiry date on the award.
LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John M. Leonard reported receiving an equity award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for his role as a non-employee director and are fully vested upon grant, with no purchase price paid. Following this award, Leonard directly holds 16,946 shares of IQVIA common stock.
GOGGINS COLLEEN A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Colleen A. Goggins received an award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for Non-Employee Directors and are fully vested upon grant, bringing her direct holdings to 14,453 shares.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 1,571 deferred shares, each linked to one share of common stock. These deferred shares settle when he ceases to be a director, upon a change in control of the company, or upon his death. Following this award, he holds 5,845 deferred shares in total.
IQVIA HOLDINGS INC. director John G. Danhakl reported an indirect acquisition of 1,571 shares of common stock on an award that was fully vested upon grant for Non-Employee Directors. These shares are held in the Danhakl Revocable Family Trust.
Following the award, the trust holds 30,612 shares of IQVIA common stock, and a related LLC controlled by the trust holds an additional 1,275 shares. The filing reflects compensation-related grants and indirect holdings, not open-market purchases or sales.
Burt Carol reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Carol Burt received an equity award of 1,571 shares of common stock as a non-employee director. The shares were fully vested upon grant and are held indirectly in the Carol Burt Hilliard Revocable Trust, bringing her indirect holdings to 7,533 shares.
IQVIA Holdings Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved the new 2026 Incentive and Stock Award Plan, which replaces the 2017 plan and supports a wide range of equity awards tied to performance measures such as revenue, adjusted EBITDA and relative total stockholder return.
As of the February 23, 2026 record date, 167,866,339 common shares were outstanding and entitled to vote. All nominated directors were elected. The advisory vote on 2025 executive compensation passed with 118,398,355 votes for and 29,398,856 against. Shareholders approved the 2026 Plan with 96,987,612 votes for and 51,006,455 against, and ratified PricewaterhouseCoopers LLP as auditor with 140,865,227 votes for. A stockholder proposal to separate the Chairman and CEO roles did not pass, receiving 36,717,802 votes for and 111,154,252 against.